Prostaglandins, Leukotrienes and Essential Fatty Acids
Volume 82, Issue 2 , Pages 87-95 , February 2010

The Effects of EPA, DHA, and Aspirin Ingestion on Plasma Lysophospholipids and Autotaxin

  • R.C. Block

      Affiliations

    • Department of Community and Preventive Medicine and the Cardiology Division, Department of Medicine, the University of Rochester School of Medicine and Dentistry, Box 644, 601 Elmwood Avenue, Rochester, New York 14642
    • Corresponding Author InformationCorresponding author. Tel.: +15852753356.
    • ,
  • R. Duff

      Affiliations

    • Pulmonary and Critical Care Division, Department of Medicine, the University of Rochester School of Medicine and Dentistry, Rochester, New York
    • ,
  • P. Lawrence

      Affiliations

    • Division of Human Nutrition, Cornell University, Ithaca, New York
    • ,
  • L. Kakinami

      Affiliations

    • Department of Community and Preventive Medicine and the Cardiology Division, Department of Medicine, the University of Rochester School of Medicine and Dentistry, Box 644, 601 Elmwood Avenue, Rochester, New York 14642
    • ,
  • J.T. Brenna

      Affiliations

    • Division of Human Nutrition, Cornell University, Ithaca, New York
    • ,
  • G.C. Shearer

      Affiliations

    • Cardiovascular Health Research Center, Sanford Research/USD, Sioux Falls, SD
    • ,
  • N. Meednu

      Affiliations

    • Pulmonary and Critical Care Division, Department of Medicine, the University of Rochester School of Medicine and Dentistry, Rochester, New York
    • ,
  • S. Mousa

      Affiliations

    • Pharmaceutical Research Institute, Albany College of Pharmacy, Albany, New York
    • ,
  • A. Friedman

      Affiliations

    • Department of Environmental Medicine, the University of Rochester School of Medicine and Dentistry, Rochester, New York
    • ,
  • W.S. Harris

      Affiliations

    • Cardiovascular Health Research Center, Sanford Research/USD, Sioux Falls, SD
    • ,
  • Mark Larson

      Affiliations

    • Augustana College, Sioux Falls, SD
    • ,
  • S. Georas

      Affiliations

    • Pulmonary and Critical Care Division, Department of Medicine, the University of Rochester School of Medicine and Dentistry, Rochester, New York

Received 19 October 2009 ,Revised 18 December 2009 ,Accepted 22 December 2009.

References 

  1. Aoki J. Mechanisms of lysophosphatidic acid production. Semin. Cell Dev. Biol. 2004;15:477–489
  2. Wu WT, Chen CN, Lin CI, Chen JH, Lee H. Lysophospholipids enhance matrix metalloproteinase-2 expression in human endothelial cells. Endocrinology. 2005;146:3387–3400
  3. Lucas A, Grynberg A, Lacour B, Goirand F. Dietary n-3 polyunsaturated fatty acids and endothelium dysfunction induced by lysophosphatidylcholine in Syrian hamster aorta. Metabolism. 2008;57:233–240
  4. Panchatcharam M, Miriyala S, Yang F, Rojas M, End C, Vallant C, et al. Lysophosphatidic acid receptors 1 and 2 play roles in regulation of vascular injury responses but not blood pressure. Circ. Res. 2008;103:662–670
  5. G. Schmitz, K. Ruebsaamen, Metabolism and atherogenic disease association of lysophosphatidylcholine, Atherosclerosis (2009).
  6. Chen G, Li J, Qiang X, Czura CJ, Ochani M, Ochani K, et al. Suppression of HMGB1 release by stearoyl lysophosphatidylcholine:an additional mechanism for its therapeutic effects in experimental sepsis. J. Lipid Res. 2005;46:623–627
  7. Yan JJ, Jung JS, Lee JE, Lee J, Huh SO, Kim HS, et al. Therapeutic effects of lysophosphatidylcholine in experimental sepsis. Nat. Med. 2004;10:161–167
  8. Aoki J, Inoue A, Okudaira S. Two pathways for lysophosphatidic acid production. Biochim. Biophys. Acta. 2008;1781:513–518
  9. Zhao Y, Natarajan V. Lysophosphatidic acid signaling in airway epithelium: role in airway inflammation and remodeling. Cell Signal. 2009;21:367–377
  10. Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J. Cell Biol. 2002;158:227–233
  11. van Meeteren LA, Ruurs P, Stortelers C, Bouwman P, van Rooijen MA, Pradere JP, et al. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol. Cell Biol. 2006;26:5015–5022
  12. Stracke ML, Krutzsch HC, Unsworth EJ, Arestad A, Cioce V, Schiffmann E, et al. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J. Biol. Chem. 1992;267:2524–2529
  13. Federico L, Pamuklar Z, Smyth SS, Morris AJ. Therapeutic potential of autotaxin/lysophospholipase D inhibitors. Curr. Drug Targets. 2008;9:698–708
  14. Tokumura A, Harada K, Fukuzawa K, Tsukatani H. Involvement of lysophospholipase D in the production of lysophosphatidic acid in rat plasma. Biochim. Biophys. Acta. 1986;875:31–38
  15. Hayashi K, Takahashi M, Nishida W, Yoshida K, Ohkawa Y, Kitabatake A, et al. Phenotypic modulation of vascular smooth muscle cells induced by unsaturated lysophosphatidic acids. Circ. Res. 2001;89:251–258
  16. Yoshida K, Nishida W, Hayashi K, Ohkawa Y, Ogawa A, Aoki J, et al. Vascular remodeling induced by naturally occurring unsaturated lysophosphatidic acid in vivo. Circulation. 2003;108:1746–1752
  17. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106:2747–2757
  18. Kereiakes DJ. Adjunctive pharmacotherapy before percutaneous coronary intervention in non-ST-elevation acute coronary syndromes: the role of modulating inflammation. Circulation. 2003;108:III22–III27
  19. Li ZG, Yu ZC, Wang DZ, Ju WP, Zhan X, Wu QZ, et al. Influence of acetylsalicylate on plasma lysophosphatidic acid level in patients with ischemic cerebral vascular diseases. Neurol. Res. 2008;30:366–369
  20. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N. Engl. J. Med. 2001;345:1809–1817
  21. Xu AS, Ohba Y, Vida L, Labotka RJ, London RE. Aspirin acetylation of betaLys-82 of human hemoglobin. NMR study of acetylated hemoglobin Tsurumai. Biochem. Pharmacol. 2000;60:917–922
  22. Rendell M, Nierenberg J, Brannan C, Valentine JL, Stephen PM, Dodds S, et al. Inhibition of glycation of albumin and hemoglobin by acetylation in vitro and in vivo. J. Lab. Clin. Med. 1986;108:286–293
  23. Larson MK, Ashmore JH, Harris KA, Vogelaar JL, Pottala JV, Sprehe M, et al. Effects of omega-3 acid ethyl esters and aspirin, alone and in combination, on platelet function in healthy subjects. Thromb. Haemost. 2008;100:634–641
  24. Lopez-Lopez A, Castellote-Bargalló A, López-Sabater M. Comparison of two direct methods for the determination of fatty acids in human milk. Chromatographia. 2006;54:743–747
  25. Yoon HR, Kim H, Cho SH. Quantitative analysis of acyl-lysophosphatidic acid in plasma using negative ionization tandem mass spectrometry. J. Chromatogr. B Analyt Technol. Biomed. Life Sci. 2003;788:85–92
  26. Zhao Z, Xiao Y, Elson P, Tan H, Plummer SJ, Berk M, et al. Plasma lysophosphatidylcholine levels: potential biomarkers for colorectal cancer. J. Clin. Oncol. 2007;25:2696–2701
  27. Zhao Z, Xu Y. Measurement of endogenous lysophosphatidic acid by ESI-MS/MS in plasma samples requires pre-separation of lysophosphatidylcholine. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2009;877:3739–3742
  28. Ferguson CG, Bigman CS, Richardson RD, van Meeteren LA, Moolenaar WH, Prestwich GD. Fluorogenic phospholipid substrate to detect lysophospholipase D/autotaxin activity. Org. Lett. 2006;8:2023–2026
  29. Hosogaya S, Yatomi Y, Nakamura K, Ohkawa R, Okubo S, Yokota H, et al. Measurement of plasma lysophosphatidic acid concentration in healthy subjects: strong correlation with lysophospholipase D activity. Ann. Clin. Biochem. 2008;45:364–368
  30. Cohen JT, Bellinger DC, Connor WE, Kris-Etherton PM, Lawrence RS, Savitz DA, et al. A quantitative risk-benefit analysis of changes in population fish consumption. American Journal of Preventive Medicine. 2005;29:325–334
  31. American Heart Association Nutrition Committee , Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation. 2006;114:82–96
  32. Lemaitre RN, King IB, Mozaffarian D, Sotoodehnia N, Rea TD, Kuller LH, et al. Plasma phospholipid trans fatty acids, fatal ischemic heart disease, and sudden cardiac death in older adults: the cardiovascular health study. Circulation. 2006;114:209–215
  33. Raitt MH, Connor WE, Morris C, Kron J, Halperin B, Chugh SS, et al. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: A randomized controlled trial. JAMA. 2005;293:2884–2891
  34. Leaf A, Albert CM, Josephson M, Steinhaus D, Kluger J, Kang JX, et al. Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake. Circulation. 2005;112:2762–2768
  35. Brouwer IA, Zock PL, Camm AJ, Bocker D, Hauer RNW, Wever EFD, et al. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: The Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) Randomized Trial. JAMA. 2006;295:2613–2619
  36. M. Lagarde, N. Bernoud, N. Brossard, D. Lemaitre-Delaunay, F. Thies, M. Croset, et al., Lysophosphatidylcholine as a preferred carrier form of docosahexaenoic acid to the brain, J. Mol. Neurosci. 16 (2001) 201-204; discussion 215–21.
  37. K. Fekete, T. Marosvolgyi, V. Jakobik, T. Decsi, Methods of assessment of n-3 long-chain polyunsaturated fatty acid status in humans: a systematic review, Am. J. Clin. Nutr. (2009).
  38. Tomsig JL, Snyder AH, Berdyshev EV, Skobeleva A, Mataya C, Natarajan V, et al. Lipid phosphate phosphohydrolase type 1 (LPP1) degrades extracellular lysophosphatidic acid in vivo. Biochem. J. 2009;419:611–618
  39. Masuda A, Nakamura K, Izutsu K, Igarashi K, Ohkawa R, Jona M, et al. Serum autotaxin measurement in haematological malignancies: a promising marker for follicular lymphoma. Br. J. Haematol. 2008;143:60–70
  40. Prestwich GD, Gajewiak J, Zhang H, Xu X, Yang G, Serban M. Phosphatase-resistant analogues of lysophosphatidic acid: agonists promote healing, antagonists and autotaxin inhibitors treat cancer. Biochim. Biophys. Acta. 1781;2008:588–594
  41. Antithrombotic Trialists’ Collaboration . Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86
  42. Dona M, Fredman G, Schwab JM, Chiang N, Arita M, Goodarzi A, et al. Resolvin E1, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets. Blood. 2008;112:848–855
  43. Harris WS. Expert opinion: omega-3 fatty acids and bleeding-cause for concern?. Am. J. Cardiol. 2007;99:44C–46C
  44. Chiang N, Hurwitz S, Ridker PM, Serhan CN. Aspirin has a gender-dependent impact on antiinflammatory 15-epi-lipoxin A4 formation: a randomized human trial. Arterioscler. Thromb. Vasc. Biol. 2006;26:e14–e17
  45. Harris WS, von Schacky C. The Omega-3 Index: a new risk factor for death from coronary heart disease?. Prev. Med. 2004;39:212–220
  46. Harris WS, Sands SA, Windsor SL, Ali HA, Stevens TL, Magalski A, et al. Omega-3 fatty acids in cardiac biopsies from heart transplantation patients: correlation with erythrocytes and response to supplementation. Circulation. 2004;110:1645–1649
  47. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N. Engl. J. Med. 2005;353:2373–2383

PII: S0952-3278(10)00019-0

doi: 10.1016/j.plefa.2009.12.005

Prostaglandins, Leukotrienes and Essential Fatty Acids
Volume 82, Issue 2 , Pages 87-95 , February 2010

Article Tools

* Image Usage & Resolution